CODX Share Price | Co-Diagnostics, Inc. Stock Analysis & Recommendation

Q: How big is Co-Diagnostics, Inc.?

Market Cap: As of Jun 18, Co-Diagnostics, Inc. has a market capitalization of 9.13 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Co-Diagnostics, Inc. reported net sales of 0.57 million and a net profit of -35.86 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 54.31 million and total assets of 71.19 million.

Q: What does Co-Diagnostics, Inc. do?

Overview: Co-Diagnostics, Inc. is a molecular diagnostics company engaged in developing, manufacturing, and marketing diagnostics technology within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025). Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025). Market cap: USD 9.13 Million (Micro Cap).Key Metrics: P/E: NA (Loss Making). Industry P/E: NA. Dividend Yield: 0.00%. Debt Equity: -0.43. Return on Equity: -74.83%. Price to Book: 0.19.Contact Details: Address: 4049 S Highland Dr, SALT LAKE CITY UT: 84124-1664. Tel: 1 801 2789769. Website: http://codiagnostics.com/

Q: Is Co-Diagnostics, Inc. overvalued or undervalued?

As of 27 March 2025, the valuation grade for Co-Diagnostics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently deemed overvalued, given its negative financial ratios and lack of profitability. Key ratios include a price-to-book value of 0.21, an EV to EBITDA of 0.26, and an ROE of -74.83%, all highlighting the company's struggles.In comparison to its peers, Co-Diagnostics, Inc. shows a less favorable position, with peers like MAIA Biotechnology, Inc. and MiNK Therapeutics, Inc. also classified as does not qualify but with varying EV to EBITDA ratios of -2.1328 and -3.4718, respectively. The company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -65.97% compared to the index's 2.44%. This further reinforces the conclusion that Co-Diagnostics, Inc. is overvalued in its current state.

Q: Is Co-Diagnostics, Inc. technically bullish or bearish?

As of 2 June 2025, the technical trend for Co-Diagnostics, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a mix of indicators. The weekly MACD and KST are mildly bullish, while the weekly RSI is bearish. The daily moving averages indicate a mildly bearish trend. Additionally, the Bollinger Bands show a bullish signal on the weekly timeframe but a mildly bearish signal on the monthly. The Dow Theory supports a mildly bullish outlook on both weekly and monthly timeframes. In terms of performance, the stock has significantly underperformed the S&P 500 over the longer term, with a 1-year return of -66.41% compared to the S&P 500's 17.14%, and a staggering 5-year return of -97.10% against the S&P 500's 96.61%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

5.63 k

Shareholding (Sep 2025)

FII

0.43%

Held by 9 FIIs

DII

95.0%

Held by 5 DIIs

Promoter

0.00%

How big is Co-Diagnostics, Inc.?

22-Jun-2025

As of Jun 18, Co-Diagnostics, Inc. has a market capitalization of 9.13 million, with net sales of 0.57 million and a net profit of -35.86 million over the latest four quarters. The company reported shareholder's funds of 54.31 million and total assets of 71.19 million as of Dec 24.

View full answer

What does Co-Diagnostics, Inc. do?

22-Jun-2025

Co-Diagnostics, Inc. is a molecular diagnostics company focused on developing and marketing diagnostic technologies in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $0 million and a net loss of $8 million, with a market cap of $9.13 million.

View full answer

Who are in the management team of Co-Diagnostics, Inc.?

22-Jun-2025

As of March 2022, the management team of Co-Diagnostics, Inc. includes Mr. Dwight Egan as Chairman, President, and CEO, along with independent directors Dr. Eugene Durenard, Mr. Edward Murphy, Mr. James Nelson, and Mr. Richard Serbin.

View full answer

Is Co-Diagnostics, Inc. overvalued or undervalued?

25-Jun-2025

As of March 27, 2025, Co-Diagnostics, Inc. is classified as "does not qualify" due to significant financial deterioration, negative ratios indicating overvaluation, and a year-to-date stock performance of -65.97%, underperforming the S&P 500's 2.44% return.

View full answer

Is Co-Diagnostics, Inc. technically bullish or bearish?

20-Sep-2025

As of June 2, 2025, Co-Diagnostics, Inc. shows a mildly bearish trend with mixed indicators, significantly underperforming the S&P 500 with a 1-year return of -66.41% and a 5-year return of -97.10%.

View full answer

Compare Co-Diagnostics, Inc. with Similar Stocks

IN8bio, Inc.Leap Therapeutics, Inc.Molecular Templates, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.27

Return on Equity

-80.80%

Price to Book

0.15

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Sep 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-79.33%

6 Months

-69.48%

1 Year

-89.15%

2 Years

-93.3%

3 Years

-97.34%

4 Years

-98.86%

5 Years

-99.5%

Co-Diagnostics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-53.33%

EBIT Growth (5y)

-230.51%

EBIT to Interest (avg)

-3.42

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.05

Tax Ratio

0.13%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

13.94%

ROCE (avg)

83.78%

ROE (avg)

18.99%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.21

EV to EBIT

0.25

EV to EBITDA

0.26

EV to Capital Employed

-0.38

EV to Sales

-10.46

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-74.83%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (4.57%)

Foreign Institutions

Held by 9 Foreign Institutions (0.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is -50.00% vs 100.00% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 23.38% vs -2.67% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.70",
          "val2": "-7.80",
          "chgp": "14.10%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.90",
          "val2": "-7.70",
          "chgp": "23.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-48,244.90%",
          "val2": "-49,461.40%",
          "chgp": "121.65%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -20.00% vs -97.08% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.52% vs -148.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.80",
          "val2": "1.00",
          "chgp": "-20.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.80",
          "val2": "-47.30",
          "chgp": "11.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.60",
          "val2": "-35.30",
          "chgp": "-6.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-56,134.70%",
          "val2": "-48,944.10%",
          "chgp": "-719.06%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.10

0.20

-50.00%

Operating Profit (PBDIT) excl Other Income

-6.70

-7.80

14.10%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.90

-7.70

23.38%

Operating Profit Margin (Excl OI)

-48,244.90%

-49,461.40%

121.65%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is -50.00% vs 100.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 23.38% vs -2.67% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.80

1.00

-20.00%

Operating Profit (PBDIT) excl Other Income

-41.80

-47.30

11.63%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-37.60

-35.30

-6.52%

Operating Profit Margin (Excl OI)

-56,134.70%

-48,944.10%

-719.06%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -20.00% vs -97.08% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.52% vs -148.59% in Dec 2023

All Annual Results

Company CV

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc.

Pharmaceuticals & Biotechnology

Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Company Coordinates

Company Details

4049 S Highland Dr , SALT LAKE CITY UT : 84124-1664

Tel: 1 801 2789769

http://codiagnostics.com/

Registrar Details

Co-Diagnostics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Co-Diagnostics, Inc.?

Watch in Real-Time

What does Co-Diagnostics, Inc. do?

Who are in the management team of Co-Diagnostics, Inc.?

Is Co-Diagnostics, Inc. overvalued or undervalued?

Is Co-Diagnostics, Inc. technically bullish or bearish?

Compare Co-Diagnostics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Co-Diagnostics, Inc.

Company Coordinates